Revolution Medicines, Inc. RVMD Proceeds From Issuance Of Common Stock From At The Market Offering

Proceeds From Issuance Of Common Stock From At The Market Offering at other companies

EnergousWATT

$31.87M+131%

Ultragenyx PharmaceuticalRARE

$272K—

Ultragenyx PharmaceuticalRARE

$272K—

FuboTVFUBO

$95K—

Tigo Energy, Inc.TYGO

$2.1M+52,450%

Cogent Biosciences, Inc.COGT

$45.71M+88.5%

FAQ

What is Revolution Medicines, Inc.'s proceeds from issuance of common stock from at the market offering?

Revolution Medicines, Inc. (RVMD) reported proceeds from issuance of common stock from at the market offering of $226.73M in Q1 2026.

What is the long-term trend for Revolution Medicines, Inc.'s proceeds from issuance of common stock from at the market offering?

Over 2 years (2021 to 2025), Revolution Medicines, Inc.'s proceeds from issuance of common stock from at the market offering has grown at a 487.0% compound annual growth rate (CAGR), from $10.1M to $347.92M.

What does proceeds from issuance of common stock from at the market offering mean?

This metric measures cash proceeds from 'at-the-market' (ATM) equity offerings, where shares are sold directly into the public market at prevailing prices. It provides companies with a flexible, low-cost method to raise capital incrementally over time. It is a vital indicator of how a company manages its cash runway through market-based equity sales.